Image Source: Unsplash

Hypera SA (HYPMY) is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics.

Hypera also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure.

The Company's 4 operating segments are (1) Consumer Health, (2) Branded Prescription, (3) Similars e Generics, (4) Skincare and Non-Retail Market.

The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018.

Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Three key data points gauge Hypera or any dividend-paying firm.

The key three are:

(1) Price

(2) Dividends

(3) Returns

Those three basic keys best tell whether any company has made, is making, and will make money.

HYPMY Price

Over the past year, Hypera’s share price fell about 21% from $8.76 to $6.92 as of Tuesday’s market close.

If Hypera’s stock trades in the range of $5.00 to $9.00 this next year, its recent $6.92 share price might rise to $7.40 by next year. Of course, HYPMY’s price could drop about the same $0.48 estimated amount or more.

My upside estimate of $0.48, however, is a few cents less than the average annual price gain by Hypera SA over the past three years.

HYPMY Dividend

Hypera has paid variable Annual dividends since January 17, 2018.  Hypera’s most recent  A dividend, of $0.25 was paid January 12, 2023 to shareholders of record since April 1st. The forward-looking $.25 annual dividend yields 3.58% at Tuesday’s share price,

HYPMY Returns

Putting it all together, we add the estimated forward-looking annual dividend of  $0.25 to my estimated price upside of $0.48 and find a $0.73 gross gain.

At Monday’s $6.92 closing price, a little over $1000 would buy 145 shares.

A $10 broker fee (if charged), paid half at purchase and half at sale, might cost us about $0.07 per share.

Subtracting that likely $0.07 brokerage cost from the $0.73 estimated gross gain per share produces a net gain of $0.66 X 145 shares = $95.70 or about a 9.5% net gain.

You might choose to pounce on Hypera SA shares. HYPMY is a specialty and generic drug manufacturing company in Brazil. Furthermore the estimated $35.80 dividend income from $1k invested is over 5 times greater than Monday’s price of a single share.

The fate of Hypera’s ongoing future price and dividend is yet to be determined.

Remember the true value of any stock is best realized through personal ownership of shares.

More By This Author:

Current Analysis: Sinopharm Group
Current Analysis: Takeda Pharmaceuticals (TKPHF)
Current Analysis: TIM SA